Influence of Intravitreal Bevacizumab Injection on Formation of Collateral Vessels in Branch Retinal Vein Occlusion

Yeng Woo Son; Seung Woo Lee

doi:10.3341/jkos.2016.57.4.582

Journal List > J Korean Ophthalmol Soc > v.57(4) > 1010554

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Son and Lee: Influence of Intravitreal Bevacizumab Injection on Formation of Collateral Vessels in Branch Retinal Vein Occlusion

Original Article

J Korean Ophthalmol Soc 2016;57(4):582-587.

Published online: 3 September 2016

DOI: https://doi.org/10.3341/jkos.2016.57.4.582

Influence of Intravitreal Bevacizumab Injection on Formation of Collateral Vessels in Branch Retinal Vein Occlusion

Yeng Woo Son, MD, Seung Woo Lee, MD

Department of Ophthalmology, Dongguk University College of Medicine, Gyeongju, Korea

Address reprint requests to Seung Woo Lee, MD Department of Ophthalmology, Dongguk University Gyeongju Hospital, #87 Dongdae-ro, Gyeongju 38067, Korea Tel: 82-54-770-8256, Fax: 82-54-772-9618 E-mail: jazzhanul@hanmail.net

Received 27 February 2015 Revised 17 June 2015 Accepted 25 January 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To evaluate the influence of retinal collateral vessels in eyes with macular edema secondary to branch retinal vein occlusion (BRVO) treated with intravitreal bevacizumab (IVB).

Methods

We reviewed the medical records of patients with BRVO who were followed up for 12 months. To compare formations of collateral vessels, the patients were divided into 2 groups. The treatment group included 20 patients (20 eyes) treated with IVB, and the control group included 41 patients (41 eyes) without treatment.

Results

In the treatment group, the mean age was 58.4 ± 9.5 years. The average number of IVB injections performed during the 12 months was 4.5 ± 2.5 (range 2 to 8). After 12 months from diagnosis, 13 eyes (65%) presented with collateral vessels. In the control group, the mean age was 60.6 ± 9.3 years and 28 eyes (68.3%) presented with collateral vessel after 12 months. There was no difference in incidence of collateral vessel formation between the treatment group and the control group (p = 0.574).

Conclusions

IVB does not influence the formation of retinal collateralization in eyes treated for macular edema secondary to BRVO.

Keywords: Bevacizumab, Collateral Vessels, Macular Edema, Retinal Vein Occlusion

References

1. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984; 98:271–82.

2. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008; 126:513–8.

3. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol. 2005; 140:695–702.

4. Ehlers JP, Decroos FC, Fekrat S. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Retina. 2011; 31:1856–62.

5. Lee YS, Kim MS, Yu SY, Kwak HW. Two-year results of intravitreal bevacizumab injection in retinal vein occlusion. J Korean Ophthalmol Soc. 2011; 52:1039–47.

6. Rabena MD, Pieramici DJ, Castellarin AA, et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007; 27:419–25.

7. Russo V, Barone A, Conte E, et al. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina. 2009; 29:511–5.

8. Koss MJ, Pfister M, Rothweiler F, et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol. 2012; 90:e98–103.

9. Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal non-perfusion in patients with retinal vein occlusion. Ophthalmology. 2013; 120:795–802.

10. Kim KS, Chang HR, Song S. Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Acta Ophthalmol. 2008; 86:925–7.

11. Sabet-Peyman EJ, Heussen FM, Thorne JE, et al. Progression of macular ischemia following intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging. 2009; 40:316–8.

12. Goldberg N, Freund KB. Progressive optic nerve collateralization after serial intravitreal ranibizumab injections for central retinal vein occlusion. Retina. 2013; 33:449–50.

13. Seo S, Yang Y. Formation of collateral vessels and new vessels in branch retinal vein occlusion. J Korean Ophthalmol Soc. 2009; 50:61–8.

14. Im CY, Lee SY, Kwon OW. Collateral vessels in branch retinal vein occlusion. Korean J Ophthalmol. 2002; 16:82–7.

15. Montero-Moreno JA, Ruiz-Moreno JM. Collateral vessels after retinal vein occlusion treated with intravitreal bevacizumab. Austin J Clin Ophthalmol. 2014; 1:1028.

Figure 1.

Changes in BCVA and CMT from baseline to 12 months after treatment in treatment group. BCVA = best corrected visual acuity; CMT = central macular thickness.

Figure 2.

Collateral vessel in branch retinal vein occlusion (white arrows; A : on the optic disc, B: around occlusion site, C: across horizontal raphe).

Table 1.

Characteristics of the patients

Variable	Treatment group (20 eyes)	Control group (41 eyes)	p-value
Sex (%)			0.287^*
Male	7 (35.0)	19 (46.3)
Female	13 (65.0)	22 (53.7)
Age (years)			0.460^†
Mean ± SD	58.4 ± 9.5	60.6 ± 9.3
Range	41-73	41-85
Underline disease (%)			0.488^*
DM	2 (10)	4 (9.8)
HTN	6 (30)	16 (39.0)
Both (DM and HTN)	10 (50)	4 (9.8)
Laterality (eyes, %)			0.430^*
Right	10 (50)	18 (43.9)
Left	10 (50)	23 (56.1)
Involved branch (eyes, %)			0.613^*
ST	9 (45)	21 (51.2)
IT	6 (30)	14 (34.1)
Macular	5 (25)	6 (14.6)
Collateral vessel formation (eyes, %)			0.574^*
Yes	13 (65)	28 (68.3)
No	7 (35)	13 (31.7)

Values are presented as mean ± SD unless otherwise indicated.

SD = standard deviation; DM = diabetes mellitus; HTN = hypertension; ST = superior temporal vein; IT = inferior temporal vein.

^* Pearson's Chi-square analysis;

^† Wilcoxon signed rank test.

Table 2.

Comparison of collateral vessel formation group and no collateral vessel formation group

	Collateral vessel formation	No collateral vessel formation	p-value^*
Treatment group
No. of patients	13	7
BCVA (log MAR)
Initial	0.67 ± 0.33	0.93 ± 0.94	0.968
At 12 months	0.25 ± 0.17	0.29 ± 0.18	0.628
CMT (μm)
Initial	552.0 ± 164.5	568.8 ± 181.5	0.843
At 12 months	314.5 ± 106.5	309.5 ± 70.8	0.451
Number of IVB injection
Mean	4.7	4.3	0.384
Range	2-7	2-8
Control group
No. of patients	28	13
BCVA (log MAR)
Initial	0.69 ± 0.49	0.64 ± 0.27	0.573
At 12 months	0.19 ± 0.10	0.24 ± 0.11	0.040

Values are presented as mean ± SD unless otherwise indicated.

BCVA = best corrected visual acuity; CMT = central macular thickness; IVB = intravitreal bevacizumab injection.

^* p-values were calculated by a Wilcoxon signed rank test.

TOOLS

Similar articles